McKesson Corporation

MCK · NYSE · Stock · Healthcare
$973.10
+1.17% today
Delayed price,

What McKesson does

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Key facts

Sector
Healthcare
Industry
Medical Distribution
Market cap
$113.45B
P/E (ttm)
26.1
Forward P/E
19.2
Dividend yield
0.39%
Beta
0.30
Profit margin
1.1%
Employees
41,600
Headquarters
Irving, TX, United States
Exchange
NYSE

Performance

1 Month
+11.3%
3 Months
+15.7%
6 Months
+12.3%
1 Year
+23.8%
5 Years
+348.9%
$723.6852-week range$999.00
Biggest setback — last 12 months
-25.4%
23 Feb 2026 → 4 May 2026
Fell from $987.37 to $736.09 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+32.2%
4 May 2026 → 14 Oct 2026
Ran from $736.09 to $973.10 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$892.28 (-8.3%)$973.10$1,061.24 (+9.1%)
3 Months$837.40 (-13.9%)$973.10$1,130.79 (+16.2%)
6 Months$786.90 (-19.1%)$973.10$1,203.36 (+23.7%)
12 Months$720.63 (-25.9%)$973.10$1,314.02 (+35.0%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 30.0%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 111 shares at $891.45 — Rutledge Napoleon B JR, SVP, Controller & CAO · 2026-09-10
Acquired 368 shares — Srinivasan Ramesh (NMN), EVP and Chief Strategy Officer · 2026-08-11
Sold 301 shares at $892.33 — Lerman Bradley E, Director · 2026-08-11
Acquired 277 shares — Hinton James H., Director · 2026-07-23
Acquired 277 shares — Doughtie Lynne M, Director · 2026-07-23
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.